30 closest matches · ranked by relevance
Small Cell Lung Cancer · Extensive Stage Lung Cancer · Chemonaive
Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants
Lung Cancer
Primary: Patient Response — 2; 1; 2; 27 participants
Lung Cancer
Primary: Number of Grade 3/4 Toxicities Patients Experienced on Maintenance Bevacizumab Following Chemoradiation for Limited Stage - Small Cell Lung Cancer (LS-SCLC) — 2; 1; 1; 1…
Lung Cancer
Primary: Overall Response Rate — 65; 50 percentage of participants
Carcinoma, Small Cell · Small Cell Lung Cancer
Primary: Objective Response Rate — 3 Participants
Small Cell Lung Cancer
Primary: Part A: Percentage of Participants Achieving an Overall Response (Overall Response Rate) — 2.6 percentage of participants
Lung Cancer
Primary: Overall Survival at 2 Years — 36.60 percentage of participants
Small Cell Lung Cancer
Primary: One-year Survival, The Percentage of Patients Who Are Alive One Year After Completing Protocol Treatment — 54 percentage of participants
Small Cell Lung Cancer
Primary: Overall Survival — 8.1; 10.6 months — p=<0.01
Lung Cancer · Cancer of Lung · Pulmonary Cancer
Primary: Response Rate (RR) — 0; 0; 2; 15 Participants
Extensive Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: Objective Response (Confirmed and Unconfirmed, Complete and Partial Responses Per RECIST) — 11; 2 percentage of participants
Lung Cancer
Primary: The Objective Overall Response — 7; 12; 7; 19 participants
Extensive Stage Small Cell Lung Cancer
Primary: Percentage of Participants Alive and Progression-free (PF) at 6 Months — 30.2 Percentage of Participants
Lung Cancer
Primary: Overall Survival (12-month Rate Reported) — 60.1; 50.8 percentage of participants — p=0.2103
Limited Stage Small Cell Lung Cancer · Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 14.5; 10.7 months
Carcinoma, Small Cell
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 57 percentage of participants
Lung Cancer
Primary: Confirmation of Tumor Targeting as Measured by the Number of Patients With Assessable Lesions Greater Than or Equal to 2 cm Measured by FDG-PET and SPECT Imaging. — 5; 5…
Extensive-Stage Small Cell Lung Cancer
Primary: 1-year Survival — 38 percentage of participants
Extensive Stage Lung Small Cell Carcinoma · Recurrent Lung Small Cell Carcinoma
Primary: Progression-free Survival (PFS) — 5.5; 4.9 months — p=0.17
Extensive Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: Objective Response Rates (Complete and Partial) Evaluated Using RECIST Criteria — 2 participants
Extensive Stage Small Cell Lung Carcinoma
Primary: Progression Free Survival (PFS) — 5.88; 5.85 Months — p=0.8072
Extensive Stage Lung Small Cell Carcinoma · Recurrent Lung Small Cell Carcinoma
Primary: Maximum Tolerated of Sunitinib Combined With Cisplatin and Etoposide (Phase I) — 25 mg/day
Carcinoma, Non-Small -Cell Lung · Ovarian Neoplasms · Small Cell Lung Carcinoma
Primary: Ph I: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of Topotecan — 1.25 mg/m^2
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
Small Cell Lung Cancer · Extensive-stage Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 1.9; 1.7 Months
Small-cell Lung Cancer
Primary: Overall Survival (OS) — 8.6; 7.6 months — p=0.9029
Small Cell Lung Cancer
Primary: Objective Response Rate — 6 Participants
Recurrent Small Cell Lung Cancer
Primary: Maximum Tolerated Dose (MTD) of Rovalpituzumab Tesirine — 0.4 mg/kg
Extensive Stage Small Cell Lung Cancer
Primary: Proportion of Patients With Objective Response by Solid Tumor Response Criteria (RECIST) — 0.697; 0.576 proportion of participants
Lung Cancer
Primary: Incidence of Chronic Neurotoxicity — 60; 85; 89 percentage of participants